Stifel initiated coverage of MoonLake Immunotherapeutics with a Buy rating and $74 price target. While admitting to have “already missed out on the run this year” with the stock up by more than 350% following data in Hidradenitis suppurativa, or HS, the firm says is “supporting a best-in-class IL-17 profile,” the analyst still sees “clear room for potential upside” on the derisking of additional indications and/or M&A.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MLTX:
- MoonLake announces full dataset from 24-week MIRA clinical trial
- MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
- MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
- MoonLake Immunotherapeutics presents 12-week data from Phase 2 MIRA trial
- Insider Trading: Major Owner at MoonLake (NASDAQ:MLTX) Continues to Grow Stake
